Most importantly, as the identification of menin as a co-factor for MLL fusions did for leukemias, VCP identified as a co-factor for the AT3 fusion oncoprotein will immediately widen the avenues of investigation into both biology and therapy for ASPS and Xp11-rearranged RCC. This evidence concerns the gene KMT2A and alveolar soft part sarcoma.